In patients with type 2 diabetes
with high CV risk
with high CV risk
CV DEATH
HAS A
NEW OPPONENT
Jardiance® (Empagliflozin) is the only type 2 diabetes pill proven to go beyond lowering A1C to reduce the risk of CV death for adults who have type 2 diabetes and heart disease
EMPA REG trial outcomes for T2D and CV disease patients
Document ID: PC-AE-101741
24/04/2023
Author: Boehringer Ingelheim
EMPA REG trial outcomes for T2D and CV disease patients
123,000
Views
100k 340
Related content
PC-AE-101741
Production date: April 2023
Production date: April 2023